Arthur He
Stock Analyst at HC Wainwright & Co.
(3.28)
# 1,065
Out of 4,984 analysts
62
Total ratings
47.54%
Success rate
4.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Maintains: Buy | $8 → $7 | $2.04 | +243.14% | 11 | Aug 15, 2025 | |
| LVTX LAVA Therapeutics | Maintains: Neutral | $1.5 → $1.24 | $1.50 | -17.33% | 11 | Aug 5, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $12.30 | +38.21% | 1 | Jul 30, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | n/a | $0.08 | - | 7 | Jul 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $6.5 → $120 | $51.07 | +134.97% | 4 | Jun 24, 2025 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $5.47 | +265.63% | 10 | Jun 17, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $75 → $85 | $24.54 | +246.37% | 2 | Jun 2, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $4.65 | - | 8 | May 20, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.68 | - | 8 | Mar 31, 2025 |
Adagene
Aug 15, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $2.04
Upside: +243.14%
LAVA Therapeutics
Aug 5, 2025
Maintains: Neutral
Price Target: $1.5 → $1.24
Current: $1.50
Upside: -17.33%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $12.30
Upside: +38.21%
Adaptimmune Therapeutics
Jul 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.08
Upside: -
Nektar Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $6.5 → $120
Current: $51.07
Upside: +134.97%
Solid Biosciences
Jun 17, 2025
Reiterates: Buy
Price Target: $20
Current: $5.47
Upside: +265.63%
Vera Therapeutics
Jun 2, 2025
Maintains: Buy
Price Target: $75 → $85
Current: $24.54
Upside: +246.37%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.65
Upside: -
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.68
Upside: -